Research programme: TRIM proteins - Myrexis

Drug Profile

Research programme: TRIM proteins - Myrexis

Alternative Names: TRIM proteins; TRIM37 protein; Tripartite motif proteins

Latest Information Update: 26 Nov 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Myriad Pharmaceuticals
  • Developer Myrexis; University of Minnesota
  • Class Proteins
  • Mechanism of Action RNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 09 Nov 2012 The Board of Directors of Myrexis announces a plan of complete liquidation and dissolution of the company
  • 30 Jun 2010 Myriad Pharmaceuticals is now called Myrexis
  • 08 Jun 2010 Suspended for HIV infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top